Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
affecting approximately 25% of the general population worldwide, and is forecasted to …

Although metabolic dysfunction-associated steatohepatitis (MASH) is rapidly becoming a
leading cause of cirrhosis worldwide, therapeutic options are limited and the number of …

Hypoxia is an important feature, which can upregulate the hypoxia‐inducible factor‐1α (HIF‐
1α) expression and promote the activation of hepatic stellate cells (HSCs), leading to liver …

The development and validation of non-invasive fibrosis tests (NITs) has changed clinical
practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease …

Introduction Obesity is considered a poor lifestyle choice.'Obesity'is not a sufficient definition
for patients, any more than 'cancer'or'arthritis' would be. A major obstacle is the lack of …

The rising prevalence of liver diseases related to obesity and excessive use of alcohol is
fuelling an increasing demand for accurate biomarkers aimed at community screening …

The definitive diagnosis of non-alcoholic steatohepatitis (NASH) currently relies on invasive
and labor-intensive liver biopsy. Here, we identified soluble CUB domain-containing protein …

The farnesoid X receptor (FXR), a ligand-activated transcription factor, plays a crucial role in
regulating bile acid metabolism within the enterohepatic circulation. Beyond its involvement …

The assessment of liver steatosis is crucial in both hepatology and liver transplantation (LT)
surgery. Steatosis can negatively impact the success of LT. Steatosis is a factor for excluding …

This narrative review highlights current evidence on non-invasive tests to predict the
presence or absence as well as the severity of metabolic dysfunction-associated …